WO2006038304A1 - リポポリサッカライドを有効成分とする肛門圧低下外用剤 - Google Patents
リポポリサッカライドを有効成分とする肛門圧低下外用剤 Download PDFInfo
- Publication number
- WO2006038304A1 WO2006038304A1 PCT/JP2004/014883 JP2004014883W WO2006038304A1 WO 2006038304 A1 WO2006038304 A1 WO 2006038304A1 JP 2004014883 W JP2004014883 W JP 2004014883W WO 2006038304 A1 WO2006038304 A1 WO 2006038304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anal
- pressure
- lipopolysaccharide
- active ingredient
- preventive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention relates to an anal pressure-reducing topical preparation containing lipopolysaccharide as an active ingredient, and an agent for preventing or treating anal-related diseases.
- LPS Lipopolysaccharide
- lipid A lipid A
- sugar lipid A
- LPS lipopolysaccharide having a repeating structure of lipid A, a high molecular phospholipid, and sugar.
- LPS is called endotoxin.
- shock shock
- endotoxin shock since many intestinal bacteria are gram-negative bacteria and there is a defense mechanism in the normal intestinal tract, bacteria and LPS cannot pass through the intestinal mucosa and therefore do not enter the living body.
- Hirschsbrung's disease is caused by a congenital deficiency in the autonomic plexus of Meissnell and Auerbach in the intestinal wall, usually confined to the distal colon. No or perturbed lesions, resulting in sustained smooth muscle spasticity, partial or complete obstruction due to accumulation of intestinal contents, and normal innervation more proximally Intestinal dilatation occurs.
- the obstruction is most common in the anus, but it can spread to various parts of the proximal colon and can extend throughout the colon and, rarely, the terminal ileum and digestive tract. Patients present with constipation and abdominal distension.
- Botulinum toxin is known to be effective in Hirschsbrung's disease, but this is due to a reduction in internal anal pressure. Also laxative administration If bowel movement adjustment and defecation guidance are performed by dietary guidance but this does not improve, internal sphincter incision is performed.
- Crohn's disease is an inflammation characterized by right lower abdominal pain and tenderness, a recurrent partial obstruction caused by intestinal stenosis, causing severe colic, abdominal distension, diarrhea, vomiting, inflammation and obstruction, malnutrition and Diffuse jejunitis leading to debilitating, and usually a late event, often with symptoms such as fever and painful abdominal masses. There is also anal pain due to spasticity of smooth muscle. Anticholinergic drugs and diphenoxylate, oral peramide, opium tincture, and codin are used as symptomatic treatments for this disease. Sulfazarazine is also used as a steroid.
- Anti-metabolites such as azathioprine 6-mercaptopurine, methotrexate, have been shown to be effective as immunosuppressants. All of these drugs have a certain effect, but in order to improve quality of life (QOL), it is also desirable to administer drugs that reduce pain by reducing anal pressure.
- QOL quality of life
- Irritable bowel syndrome is not a single disease, but complains of diarrhea or alternation of diarrhea and constipation and associated abdominal symptoms, but organic lesions that explain these symptoms are not proven in the intestine and related organs It is called in this way generically. It is known that pain due to irritable colorectal syndrome is due to increased anal pressure (Krag E, Irritable bowel syndrome: current concepts and future trends, Scandinavian Journal of Gastroenterology Suppl, Scandinavia, 1985, 109, pp.107- 115). Although there is no specific symptom of this disease, dull pain in the right lower abdomen is often associated with colic and repeated diarrhea and constipation. Reducing anal pressure and relieving pain in the lower abdomen is also an important treatment for increasing QOL.
- Anal fist muscle syndrome is a disease in which the depths of the anus suddenly hurt despite the absence of hemorrhoids and cuts in the anus, and the cause is unknown. Pain occurs suddenly and becomes severe pain that can be tightened. There are various causes, but the most common is excessive anal sphincter Pain is caused by various contractions. Reducing anal pressure to relieve this pain is a very effective treatment.
- anal sphincter muscles especially anal fistula muscles, are abnormally increased in anal sphincter disorders.
- Macrocolonia is known to develop due to muscle tension of the anal sphincter muscle due to myotonic dystrophy. Tension reaction is recognized. It is also known that megacolon is caused by abuse of laxatives, pseudo obstruction of the large intestine, and persistent spasm of the anal sphincter due to perianal pain.
- anal pressure has been increased in fissures such as fissures.
- the anal sphincter contracts, and as a result, the tissues and nerves in the anus are compressed, causing intense pain.
- Surgery is performed for the purpose of treating these diseases, but pharmacological prophylaxis has been achieved because patients and their families often resist surgery and often suffer from fecal incontinence. Or treatment is desired.
- nitroglycerin ointment has a problem that side effects such as headache and burning of the anus occur frequently, and botulinum toxin injection requires a visit. Disclosure of invention
- An object of the present invention is to provide an anal pressure-reducing topical preparation containing lipopolysaccharide as an active ingredient, a method for lowering anal pressure, and a prophylactic or therapeutic agent for anal-related diseases.
- the present inventors have found that a preparation containing lipopolysaccharide reduces anal pressure and completed the present invention. That is, the present invention provides the following external preparations for lowering anal pressure, methods for lowering anal pressure, and preventive or therapeutic agents for anal-related diseases.
- Item 1 An anal pressure-reducing topical preparation containing lipopolysaccharide as an active ingredient.
- Item 2 The anal pressure-reducing topical preparation according to Item 1, which is applied to the anorectal region and around the anus.
- Item 3 A method for decreasing anal pressure, wherein the anal pressure-reducing topical preparation described in Item 1 or 2 is applied to the anus.
- Item 4 The method for reducing anal pressure according to Item 3, wherein the application part is an anal mucosa or a trauma site.
- Item 5. A prophylactic or therapeutic agent for anal fissure or hemorrhoids comprising lipopolysaccharide as an active ingredient
- Item 6. A prophylactic or therapeutic agent for constipation comprising lipopolysaccharide as an active ingredient.
- Item 7 A preventive or therapeutic agent for Hirschsbrung's disease comprising lipopolysaccharide as an active ingredient.
- Item 8 A preventive or therapeutic agent for Crohn's disease comprising lipopolysaccharide as an active ingredient.
- Item 9 A preventive or therapeutic agent for irritable bowel syndrome comprising lipopolysaccharide as an active ingredient.
- Item 10 A prophylactic or therapeutic agent for anal sphincter dysfunction comprising lipopolysaccharide as an active ingredient.
- Item 1 A preventive or therapeutic agent for megacolon comprising lipopolysaccharide as an active ingredient.
- Item 12 A prophylactic or therapeutic agent for anal fistula syndrome comprising lipopolysaccharide as an active ingredient.
- Item 1 A prophylactic or therapeutic agent for leprosy comprising lipopolysaccharide as an active ingredient.
- the anal pressure lowering external preparation, anal pressure lowering method, and anal preventive or therapeutic agent of the present invention are characterized by comprising lipopolysaccharide (hereinafter sometimes referred to as LPS) as an active ingredient.
- LPS lipopolysaccharide
- Anal-related diseases include hemorrhoids (eg anal fissure, hemorrhoids), constipation, Hirschsprung's disease, Crohn's disease, irritable bowel syndrome, anal sphincter disorder, anal fistula syndrome
- the anal pressure-reducing external preparation of the present invention is useful for the prevention or treatment of these diseases because the lipopolysaccharide contained therein has an anal pressure-reducing action.
- LPS is a structural component characteristic of the cell wall of Gram-negative bacteria and is present in the outer membrane (H. Mayer, RNTharanthan, J, weckesser, "Methods in Microbiology", ed. By G. Gottschalk, Vol 18, p.157, Academic Press, Florida (1985)). LPS was prepared by Westphal's hot phenol water extraction method (O. Westphal, K. Jann, "Methods in Carbohydrate Chemistry, ed. By R. Whistler, Vol. 5, p.
- the preparation form of the external preparation for reducing anal pressure and the preventive or therapeutic agent for anus-related diseases of the present invention is not particularly limited as long as it is a form applicable to the anus.
- ointments, suppositories, creams, gels, liniments, lotions, emulsions, powders, suspensions, aerosols, etc., and plasters, poultices examples include loop agents and plaster agents.
- An ointment more preferably an ointment.
- the amount of lipopolysaccharide as an active ingredient in the anal pressure-reducing topical preparation of the present invention and the prophylactic or therapeutic agent for anus-related diseases is not particularly limited as long as an anal pressure-reducing action is observed. It can be appropriately selected according to the patient's symptoms. For example, in the case of an ointment, an appropriate amount of ointment containing an effective amount of LPS is usually applied to the affected area one to several times a day.
- Any base may be used as long as it is pharmaceutically acceptable, and conventionally known ones can be used as appropriate.
- Higher fatty acids higher alcohols such as cetanol, octyldodecanol and stearyl alcohol; polyethylene glycol (eg, macrogol 400, macrogol 400, etc.); polyhydric alcohols such as propylene glycol and dariserine; Monore Fatty acid esters such as inic acid ester, glyceride stearate, octyldodecyl myristate, isopropyl myristate, hard fat; water, physiological saline, phosphate buffer and the like.
- hydrocarbons for example, in the case of an ointment, hydrocarbons, fatty acid esters, gelled hydrocarbons, beeswax, polyethylene glycol, etc. are used.
- hydrocarbons, surfactants, water, glycerin, cetanol, stearyl alcohol, etc. are used.
- hydrocarbons, water, strong l-poxyvinyl polymer, glycerin, cetanol, propylene glycol, etc. are used.
- water, surfactant, carboxyvinyl polymer, lower alcohols, etc. are used for the gel.
- Surfactants include, for example, polysorbate 80, lecithin derivatives, propylene dalycol fatty acid esters such as self-emulsifying propylene dalycol monostearate, glycerin fatty acid esters such as glyceryl monostearate, and polyoxyethylene glycerin.
- Fatty acid ester polyglycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbin fatty acid ester, polyoxyethylene sorbite fatty acid ester, polyoxyethylene alkylphenyl formaldehyde condensate, polyoxyethylene castor oil, polyoxyethylene Hard ⁇ Castor oil, polyoxyethylene sterol, hydrogenated sterol, polyethylene glycol fatty acid ester, polyoxyethylene cetyl ether and other polyoxy Ether, polyoxyethylene alkyl phenyl ether, polyoxyethylene lanolin, lanolin alcohol, beeswax derivative, polyoxyethylene alkylamine 'fatty acid amide, polyoxyethylene alkyl ether phosphate, phosphate, sodium carboxymethyl starch, Hydrophobic soft caustic anhydride, polymer emulsifier and the like.
- darriselin fatty acid ester polyoxyethylene glycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbin fatty acid ester, polyoxyscherylene hydrogenated castor oil, polyoxy Kischylene alkyl ether is often used.
- solubilizing agents such as polyvinylpyrrolidone; inorganic fillers such as strong orine, bentonite, zinc oxide, and titanium oxide; anti-aging agents; pH regulators such as triethanolamine; glycerin, propylene dallicol Moisturizers such as methyl paraoxybenzoate, propyl paraoxybenzoate, benzalkonium chloride, benzethonium chloride, citrate, sodium citrate, paraoxybenzoates, humic acid, borax, camphor, etc .; xanthan gum, A sticking agent or a sticking agent such as sodium chondroitin sulfate, liquid paraffin, glycerin, polyethylene glycol, or polyvinylpyrrolidone may be added.
- solubilizing agents such as polyvinylpyrrolidone
- inorganic fillers such as strong orine, bentonite, zinc oxide, and titanium oxide
- anti-aging agents pH regulators such as triethanolamine
- any pharmaceutically acceptable one can be used, and conventionally known ones can be used, for example, acrylic adhesive, rubber adhesive, silicon adhesive, Examples thereof include urethane adhesives, and acrylic adhesives and rubber adhesives are preferably used.
- acrylic adhesive for example, acrylic adhesive, rubber adhesive, silicon adhesive, Examples thereof include urethane adhesives, and acrylic adhesives and rubber adhesives are preferably used.
- any of solvent-based, emulsion-based, hot-melt-based, etc. can be used as a property of the pressure-sensitive adhesive when spread on the support.
- acrylic pressure-sensitive adhesive examples include pressure-sensitive adhesives mainly composed of polyalkyl (meth) acrylate obtained by copolymerization of alkyl (meth) acrylate, and can be copolymerized with alkyl (meth) acrylate. It may be a polyfunctional monomer or a copolymer with other vinyl monomers.
- alkyl (meth) acrylate examples include 2-ethylhexyl (meth) acrylate, dodecyl (meth) acrylate and the like.
- the above Examples of the polyfunctional monomer include 1,6-hexane glycol diacrylate and tetraethylene glycol diacrylate.
- Examples of the other vinyl monomer include N-pinyl — 2—. Examples include pyrrolidone and vinyl acetate.
- Examples of the rubber-based pressure-sensitive adhesive include pressure-sensitive adhesives mainly composed of natural rubber, styrene-isoprene-styrene block copolymer, styrene 1-year-old refin-styrene block copolymer, and generally include rosin and zK.
- a tackifier such as rosin, rosin ester, terbene resin, terpene phenol resin, petroleum resin, coumarone resin, coumarone-indene resin is added.
- the support is appropriately selected according to the dosage form (for example, a poultice, a tape, etc.), but is preferably a non-permeable or poorly permeable drug, such as cellulose acetate, Tillcellulose, polyethylene, polypropylene, polyvinyl chloride, vinyl acetate-vinyl chloride copolymer, ethylene monoacetate vinyl copolymer, ethylene-vinyl acetate carbon monoxide copolymer, ethylene monobutyl acrylate-carbon monoxide Examples thereof include resin films such as copolymers, polyvinylidene chloride, polyurethane, nylon, polyethylene terephthalate, and polybutylene terephthalate; aluminum sheets, woven fabrics, nonwoven fabrics, and the like, and laminated sheets thereof.
- a non-permeable or poorly permeable drug such as cellulose acetate, Tillcellulose, polyethylene, polypropylene, polyvinyl chloride, vinyl acetate-vinyl chloride copolymer,
- the dosage of the anal pressure-reducing topical preparation and the prophylactic or therapeutic agent for anus-related diseases of the present invention varies depending on the type of disease and the level of symptoms, but the daily dose to patients is usually 0.3 to 3 in terms of LPS.
- the amount is 3000 ng / kg, preferably 3 to 3000 ng / kg, more preferably 3 to 300 ng / kg, which is used once or divided into appropriate times for the affected area;
- the external preparation for anal pressure reduction and the preventive or therapeutic agent for anal-related diseases of the present invention are produced by a conventionally known method according to the dosage form.
- the raw material base is heated and melted, mixed, partially cooled, and then LPS is added to the base and kneaded.
- the solid base is dissolved in a water bath and then maintained at about 75 ° C, and then the water-soluble base is dissolved in water at the same or slightly higher temperature. Add the warmed product to LPS and add LPS to knead.
- a polymer is added to water and heated to swell.
- a water-soluble base and bacteria dissolved in warm solvent are added, mixed and dissolved, and then cooled to produce.
- a polymer is added to water and heated to swell.
- a 7j-soluble base dissolved in a solvent LPS is added to this, mixed and dispersed, and then cooled to produce.
- the mixing / dissolving method includes a method using a mortar and pestle, a method using a kneader, a method using an emulsifier, and the like. The method is appropriately selected depending on the properties of the base and the amount of preparation.
- an external preparation for reducing anal pressure is applied to the anus. That is, lipopolysaccharide or an external preparation containing this is applied to the anus.
- the application amount of the anal pressure-reducing external preparation is the same as the above dose.
- the present invention provides a method for preventing or treating anal fissure or hemorrhoid, a method for preventing or treating constipation by applying lipopolysaccharide or an external preparation containing the same to the anus as an active ingredient.
- Hirschsbrunn disease prevention or treatment method Crohn disease prevention or treatment method, irritable bowel syndrome prevention or treatment method, anal sphincter disorder prevention or treatment method, megacolon prevention or treatment method, anus Includes methods for preventing or treating fistula syndrome.
- conditions such as the application amount are the same as those in the method for reducing anal pressure of the present invention.
- the anal pressure-reducing action according to the present invention is considered to be exerted by the administration of L PS to the anorectal site and around the anus to relax the anal sphincter and reduce the anal pressure.
- FIG. 1 is a graph showing the rate of change in the number of anal pressure contractions 2 hours and 4 hours after application of the LPS diluent. From the left, the bar indicates the solvent (0.3 mLVkg), 0.3 ng / kg LPS, 3 ng / kg LPS, 30 ng / kg LPS, 300 ng / kg LPS, 3000 ng / kg LPS.
- FIG. 2 is a graph showing the change rate of the anal pressure area 2 hours and 4 hours after application of the LPS diluent.
- Solvent 0.3 mL / kg
- 0.3 ng / kg LPS 0.3 ng / kg LPS
- 3 ng / kg LPS 3 ng / kg LPS
- 30 ng / kg LPS 300 ng / kg LPS
- 3000 ng / kg LPS are shown.
- FIG. 3 is a graph showing the rate of change in blood pressure 2 hours and 4 hours after application of LPS diluent.
- Solvent 0.03mL7ka
- 0.3na / kg LPS 0.3na / kg LPS
- 3ng / kg LPS 3ng / kg LPS
- 30ng / kg LPS 300 ng / kg LPS and 3000 ng / kg LPS are shown.
- FIG. 4 is a graph showing the relationship between the amount of L PS applied and the rate of change in anal pressure contraction number.
- FIG. 5 is a graph showing the relationship between the amount of L PS applied and the rate of change in anal pressure area.
- FIG. 6 is a graph showing the effect of L-NAME (A) or aminoguanidine (B), a nitrogen monoxide inhibitor, on the anal pressure contraction-reducing action of ointment containing E. coli dead bacteria suspension.
- the arrow indicates the time when the inhibitor was administered.
- FIG. 7 is a graph showing the effect of (A) or aminoguanidine (B), which is a nitric oxide inhibitor, on the anal pressure area reducing action of the ointment containing E. coli dead bacteria suspension.
- the arrow indicates the time when the inhibitor was administered.
- Example 1 Effect of topical application of commercially available LPS on rat internal pressure and blood pressure
- the anal pressure was evaluated by the area under the anal pressure curve for 7 minutes (anal pressure area) and the number of contractions of 20 mmH 2 O or more (anal pressure contraction number) from 1 to 8 minutes after the start of measurement of each anal pressure measurement record.
- the results of the evaluation are shown in Figures 1 to 5 in terms of the rate of change (%) with respect to the results of the intraanal pressure and blood pressure after application, with the average of the values measured twice before application as 100%.
- Figures 1, 2, 4 and 5 show that both the number of anal pressure contractions and the area of anal pressure are applied from 2 to 4 o'clock.
- LPS decreased in a dose-dependent manner until later, confirming that LPS is effective in reducing anal pressure.
- no extreme decrease in blood pressure was observed.
- LPS endotoxin shock was not observed as far as rats were observed.
- a recorder (11-G4113-01, Gould) was connected to a recorder (UNICODER, U-228, JEOL) and a differential pressure transducer (DP45, validin). After calibration with negative water pressure, a balloon-mounted catheter for measuring the pressure inside the anus was connected to the differential pressure transducer, and the pressure inside the anus was started.
- the anal pressure was determined by placing Slc: SD male rats in an abdominal position on an experimental table without anesthesia and holding them lightly, using two balloons from Vinograd et al. (Vinograd I et al .: Ani mal model for the Eur Surg Res 17: 259-263, 1985), measured according to studv of internal anal sphincter activity. That is, one balloon (MB-5, outer diameter 3mm, length 15mm, made by Star Medical) is attached to the tip of a catheter (French size; 5Fr, outer diameter 1.7mm) with surgical thread (No.3) Two catheters were connected to create a catheter for measuring the internal pressure of the anus with two balloons (total length of two balloons: about 2.5 cm).
- a pressure differential transducer (DP45, Paridyne) to the anal balloon, insert the tip balloon into the rectum, and the posterior balloon into the anus, and keep it in a fixed position for about 10 minutes.
- Anal pressure was measured.
- the anal pressure catheter and balloon were filled with water (the balloon was injected with about 0.15-0.2 m of water and inflated slightly).
- the rectal balloon was temporarily inflated with about 0.7 to 0.8 mL of water to confirm the presence of the rectal anal reflex.
- the intraanal pressure was evaluated by the area under the anal pressure curve for 7 minutes (anal pressure area) and the number of contractions of 20 mmH 2 O or more (anal pressure contraction number) from 1 to 8 minutes after the start of measurement of each internal pressure measurement record.
- Anal pressure area Anal pressure curve for Macintosh “Adobe Photoshop ver.3.0J Traces the path of one layer function in the software, reverses the pressure curve inside the black, and reverses the black area for Macintosh. Image 1.62 ”.
- the number of anal pressure contractions was 20 mmH 2 O or more. Furthermore, the rate of change (%) of the value of each measurement time relative to the previous value (0 hour) was calculated for each evaluation.
- Blood pressure was measured noninvasively using a rat mouse sphygmomanometer (Muromachi Kikai Co., Ltd., MK-200 0) immediately after each anal pressure measurement.
- the anal pressure was measured twice before application, and the average value was taken as the previous value (0 hour). After measuring the previous value, the LPS dilution was applied to the anus in amounts of 0.3 ng / kg, 3 ng / kg, 30 ng / kg, 300 ng / kg and 3000 ⁇ g / kg per kg of body weight. Similarly, 0.3 mL / kg was applied to the blank. Anal pressure and blood pressure were measured 2 and 4 hours after application.
- Example 2 Effect of Nitric Oxide Synthase Inhibitor in Ointment Containing Escherichia coli Suspension Suspension Using four Slc: SD male rats (9-10 weeks old, SLS Japan, Inc.), E.
- coli containing LPS The effect of topical application of a dead fungus suspension-containing ointment (commercially available from Maruho Co., Ltd.) on the intraanal pressure was examined.
- the ointment was applied into the rat anus in an amount of 160 mg / l ⁇ g. 3 hours after application, it is a nitric oxide synthase inhibitor and contains N AME ( ⁇ -nitro-realginine methyl ester) or aminoguanidine Distilled water for injection was dropped into the anus (inhibitor dose was 10 mg per anus).
- the same measurement was performed on rats (4 animals) and placebo (4 animals) to which the ointment was applied without adding a nitric acid-nitrogen synthesis inhibitor.
- LPS as an active ingredient has an anal pressure-lowering effect, so it has anal-related diseases (eg anal fissures, hemorrhoids such as hemorrhoids), constipation, Hirschskarenda disease, Crohn's disease, It is useful for the prevention or treatment of anal sphincter disorders, anal fistula syndrome, megacolon, anal sphincter disorders, hemorrhoids, etc.
- anal-related diseases eg anal fissures, hemorrhoids such as hemorrhoids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/014883 WO2006038304A1 (ja) | 2004-10-01 | 2004-10-01 | リポポリサッカライドを有効成分とする肛門圧低下外用剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/014883 WO2006038304A1 (ja) | 2004-10-01 | 2004-10-01 | リポポリサッカライドを有効成分とする肛門圧低下外用剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038304A1 true WO2006038304A1 (ja) | 2006-04-13 |
Family
ID=36142394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014883 WO2006038304A1 (ja) | 2004-10-01 | 2004-10-01 | リポポリサッカライドを有効成分とする肛門圧低下外用剤 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006038304A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6452725A (en) * | 1987-08-24 | 1989-02-28 | Nippon Kayaku Kk | New formation agent for blood vessel |
JPH08198902A (ja) * | 1995-01-27 | 1996-08-06 | Denichi Mizuno | 低分子量リポポリサッカライド |
JPH08245702A (ja) * | 1995-03-13 | 1996-09-24 | Denichi Mizuno | 高分子量リポポリサッカライド |
-
2004
- 2004-10-01 WO PCT/JP2004/014883 patent/WO2006038304A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6452725A (en) * | 1987-08-24 | 1989-02-28 | Nippon Kayaku Kk | New formation agent for blood vessel |
JPH08198902A (ja) * | 1995-01-27 | 1996-08-06 | Denichi Mizuno | 低分子量リポポリサッカライド |
JPH08245702A (ja) * | 1995-03-13 | 1996-09-24 | Denichi Mizuno | 高分子量リポポリサッカライド |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11458190B2 (en) | Mussel adhesive protein product and use thereof for treating mucosal inflammation | |
CN101035517B (zh) | 具有活性成分位点和时间-可控胃肠释放的片剂 | |
JP5631053B2 (ja) | 門脈圧亢進症の予防及び/又は治療 | |
EP0925046A1 (en) | Topical formulations and methods for treating hemorrhoidal pain | |
WO2007048220A2 (en) | Trazodone composition for once a day adminisitiation | |
RU2681930C2 (ru) | Применение андрографолида в получении фармацевтического препарата для лечения воспалительного заболевания кишечника, микропеллета с андрографолидом для целенаправленной доставки в кишечник и способ ее получения | |
US20050089577A1 (en) | Liquid matrix undergoing phase transfer in vivo and liquid oral preparations | |
TW585762B (en) | Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases | |
JPS5841821A (ja) | 最少化された胃の損傷を示す抗炎症組成物 | |
JP4850821B2 (ja) | リパーゼ阻害物質の使用 | |
JP4618970B2 (ja) | 肛門圧低下外用剤 | |
KR20210048801A (ko) | 설글리코타이드를 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 조성물 | |
JP4632644B2 (ja) | リポポリサッカライドを有効成分とする肛門圧低下外用剤 | |
TW201601715A (zh) | 膀胱‧尿道協同失調改善劑 | |
WO2006038304A1 (ja) | リポポリサッカライドを有効成分とする肛門圧低下外用剤 | |
US20180207135A1 (en) | Oxymetazoline for the treatment of ano-rectal disorders | |
McBride et al. | Intensive care of patients with spinal trauma | |
RU2293579C1 (ru) | Способ профилактики спаечной болезни брюшины после лапаротомии у детей | |
ES2243068T3 (es) | Formulaciones farmaceuticas que comprenden beclometasona dipropionato para el tratamiento de la enfermedad intestinal inflamatoria. | |
AU2002212120A1 (en) | Lipase inhibitors for the treatment of dyspepsia | |
WO2023102491A1 (en) | Methods for treating gastrointestinal inflammatory disease | |
Spector | Antileukotriene Agents in the Management of Asthma | |
KR20050057105A (ko) | 하복부 및(또는) 회음부의 동통 개선제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 04773685 Country of ref document: EP Kind code of ref document: A1 |